Blau syndrome and latent tubercular infection: an unresolved partnership

Int J Rheum Dis. 2014 Jun;17(5):586-7. doi: 10.1111/1756-185X.12330. Epub 2014 Mar 20.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Arthritis
  • Cranial Nerve Diseases / complications*
  • Cranial Nerve Diseases / diagnosis
  • Cranial Nerve Diseases / drug therapy
  • Cranial Nerve Diseases / genetics
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Latent Tuberculosis / complications*
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / drug therapy
  • Mutation
  • Nod2 Signaling Adaptor Protein / genetics
  • Risk Factors
  • Sarcoidosis
  • Synovitis / complications*
  • Synovitis / diagnosis
  • Synovitis / drug therapy
  • Synovitis / genetics
  • Time Factors
  • Treatment Outcome
  • Uveitis / complications*
  • Uveitis / diagnosis
  • Uveitis / drug therapy
  • Uveitis / genetics

Substances

  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antitubercular Agents
  • Immunosuppressive Agents
  • NOD2 protein, human
  • Nod2 Signaling Adaptor Protein

Supplementary concepts

  • Blau syndrome